Sun-Young Kong, MD, PhD


Associate Professor
Department of System Cancer Science, GCSP
Chief
Translational Epidemiology Branch
Research Institute
National Cancer Center/Department of laboratory Medicine
National Cancer Center
Goyang, Gyeonggi, Republic of Korea
South Korea

Biography

EDUCATION AND TRAINING

•(2005) PhD(Laboratory Medicine), College of Medicine, Sungkyunkwan University, Seoul, Republic of Korea
•(2001) MS (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea
•(1997) MD (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea

PROFESSIONAL EXPERIENCES

•(2005-Present) Faculty: Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2009-2011) Research Fellowship: Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
•(2003-2005) Fellowship: Laboratory Medicine, Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2002-2003) Fellowship: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1998-2002) Residency: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1997-1998) Internship: Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea

Research Interest

Her research interests include: To develop translational biomarker for cancer diagnosis and therapeutics. We have been published papers for tumor marker in blood including cytokines, circulating tumor cells, and pharmacogenetic markers.

Scientific Activities

INTERNATIONAL COLLABORATION

• Koichi Matsuda, Human Genome Center, the University of Tokyo, Tokyo, Japan
• Kenneth C. Anderson, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA

Publications

1. Tai YT, Horton HM, Kong SY, et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012; 119(9): 2074-2082. doi: 10.1182/blood-2011-06-364521.
2. Kong SY, Han MH, Yoo HJ, et al. Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer. Ann Surg Oncol. 2011. doi: 10.1245/s10434-011-1943-5.
3. Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011; 104(7): 1126-1134. doi: 10.1038/bjc.2011.24.
4. Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011; 104(7): 1126-1134. doi: 10.1038/bjc.2011.24.
5. Han MH, Eom HS, Park WS, et al. Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood. Leuk Res. 2010; 34(9): 1127-1131. doi: 10.1016/j.leukres.2009.11.028.
6. Kong SY, Lim HS, Nam BH, et al. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 2009; 10(7): 1147-1155. doi: 10.2217/pgs.09.48.
7. Kong SY, Park JW, Kim JO, et al. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009; 135(8): 1091-1098. doi: 10.1007/s00432-009-0549-9.
8. Lee HL, Eom HS, Yun T, et al. Serum and urine levels of interleukin-8 in patients with non-Hodgkins lymphoma. Cytokine. 2008; 43(1): 71-75. doi: 10.1016/j.cyto.2008.04.004.
9. Kong SY, Lee HL, Eom HS, et al. Reference intervals for circulating angiogenic cytokines. Clin Chem Lab Med. 2008; 46(4): 545-550. doi: 10.1515/CCLM.2008.092.
10. Kong SY, Ki CS, Yoo BC, Kim JW. UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers. Cancer Sci. 2008; 99(2): 340-344. doi: 10.1111/j.1349-7006.2007.00693.x.
11. Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007; 46(2): 446-455. doi: 10.1002/hep.21720
12. Kong SY, Ki CS, Kim HJ, et al. Evaluation of imprecision for short tandem repeats analysis using mixed blood cells in variable concentrations. Clin Chem. 2004; 50(11): 2193-2195. doi: 10.1373/clinchem.2004.036103